Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. infarm

INFarm SIGNED

A unique, interferon-based veterinary therapy to minimize antimicrobial overuse in cattle and tackle the societal global problem of antimicrobial resistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 INFarm project word cloud

Explore the words cloud of the INFarm project. It provides you a very rough idea of what is the project "INFarm" about.

prevent    mis    strengthen    royalty    milestone    affordable    alternatives    121    largely    alternative    upfront    overuse    anti    threat    infections    demand    risk    drugs    treat    plan    appropriate    2050    public    business    income    clear    validation    immune    viral    receive    livestock    billion    amr    output    stimulating    commercial    abundant    chain    return    health    infrastructure    sustainable    renounce    global    antimicrobials    deal    licensing    respectively    company    healthy    give    maximize    million    payments    infective    animals    clinical    safe    therapy    lack    markets    mission    cattle    chance    addressable    accounting    pressure    keep    humans    94    antimicrobial    farmpharma    deaths    bacterial    minimize    farmers    perform    putting    solutions    feasibility    strategy    ip    realizing    resistance    reduce    volume    pharmaceutical    commercialization    commercialize    thereby    interferox    optimal    enormous    solution    consolidated    interferon    total    market    completing    77    hindering   

Project "INFarm" data sheet

The following table provides information about the project.

Coordinator		 FARMPHARMA AB 

Organization address
address: VIRDINGS ALLE 32B
city: UPPSALA
postcode: 754 50
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website https://www.farmpharma.se/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FARMPHARMA AB SE (UPPSALA) coordinator 50˙000.00

Map

 Project objective

The rise of antimicrobial resistance (AMR) is a major threat to global public health as it will cause 10 million deaths per year by 2050. The rise in AMR is largely driven by the abundant mis- and overuse of antimicrobial drugs in humans and animals. As such, there is a strong demand to reduce the use of antimicrobials in animals, putting cattle farmers under enormous pressure to change their current way of working. However, the lack of appropriate alternatives is hindering them to renounce from (over)using antimicrobials as their production output and income are at risk.

At FarmPharma, we are on the mission to provide effective, safe and affordable solutions to keep livestock animals healthy and well. To do so, we are developing InterferOx, an interferon-based, immune-stimulating, anti-infective therapy for cattle with the unique ability to treat AND prevent viral AND bacterial infections. InterferOx can thus minimize the use of antimicrobials in cattle by providing farmers an effective and sustainable alternative, thereby providing a solution for the rise in AMR.

The global market volume is 1.5 billion cattle, with our total addressable markets of Europe and US accounting for 121 and 94 million, respectively. With InterferOx, we respond to the trends and needs of our €1.7 billion target market: the cattle antimicrobials market. We aim to commercialize InterferOx via a licensing deal with a pharmaceutical company after completing clinical validation. In return, we will receive upfront, milestone and royalty payments with an estimated value of €77.8 million within the next 7 years.

To maximize our chance of realizing this promising future, we will perform a feasibility study, focusing on market analysis, commercialization strategy, IP strategy and value chain, to deliver a consolidated business plan. This will give us a clear understanding of the commercial potential of InterferOx, strengthen our current infrastructure, and define our optimal business strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INFARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More